{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.46","value":"18.1"},{"groupId":"OG001","spread":"29.26","value":"19.8"}]}],"title":"Appetite Loss Scale: Baseline (n=226, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.77","value":"10.2"},{"groupId":"OG001","spread":"24.36","value":"14.5"}]}],"title":"Appetite Loss Scale: Cy4D1 (n=189, 92)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.35","value":"80.6"},{"groupId":"OG001","spread":"22.76","value":"81.8"}]}],"title":"Cognitive Functioning Scale: Baseline (n=227, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.31","value":"83.9"},{"groupId":"OG001","spread":"18.54","value":"85.8"}]}],"title":"Cognitive Functioning Scale:Cy4D1 (n=190,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.94","value":"14.8"},{"groupId":"OG001","spread":"26.92","value":"16.8"}]}],"title":"Constipation Scale: Baseline (n=225, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.16","value":"15.1"},{"groupId":"OG001","spread":"23.53","value":"12.5"}]}],"title":"Constipation Scale: Cy4D1 (n=188, 93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.05","value":"9.3"},{"groupId":"OG001","spread":"18.98","value":"8.8"}]}],"title":"Diarrhoea Scale: Baseline (n=226, 110)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.47","value":"9.3"},{"groupId":"OG001","spread":"14.95","value":"6.5"}]}],"title":"Diarrhoea Scale: Cy4D1 (n=189, 93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.89","value":"27.1"},{"groupId":"OG001","spread":"27.63","value":"23.9"}]}],"title":"Dyspnoea Scale: Baseline (n=225, 109)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.71","value":"15.9"},{"groupId":"OG001","spread":"26.78","value":"22.3"}]}],"title":"Dyspnoea: Cy4D1 (n=189, 91)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.45","value":"73.8"},{"groupId":"OG001","spread":"25.7","value":"72.9"}]}],"title":"Emotional Functioning Scale: Baseline (n=226, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.62","value":"82.5"},{"groupId":"OG001","spread":"18.48","value":"80.6"}]}],"title":"Emotional Functioning Scale: Cy4D1(n=190,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.72","value":"38"},{"groupId":"OG001","spread":"27.01","value":"36.9"}]}],"title":"Fatigue Scale: Baseline (n=226, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.39","value":"29.2"},{"groupId":"OG001","spread":"23.00","value":"30.8"}]}],"title":"Fatigue Scale: Cy4D1(n=189, 93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.69","value":"8.9"},{"groupId":"OG001","spread":"25.26","value":"13.6"}]}],"title":"Financial Difficulties Scale: Baseline (n=224,110)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.64","value":"7.4"},{"groupId":"OG001","spread":"19.88","value":"9.3"}]}],"title":"Financial Difficulty Scale: Cy4D1(n=189,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.18","value":"5"},{"groupId":"OG001","spread":"18.49","value":"7.4"}]}],"title":"Nausea, Vomiting Scale: Baseline (n=227, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.51","value":"5.5"},{"groupId":"OG001","spread":"17.81","value":"7.5"}]}],"title":"Nausea, Vomiting Scale: Cy4D1 (n=189,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.57","value":"22.9"},{"groupId":"OG001","spread":"25.66","value":"21.5"}]}],"title":"Pain scale: Baseline (n=228, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.09","value":"17.9"},{"groupId":"OG001","spread":"25.98","value":"17.7"}]}],"title":"Pain scale: Cy4D1 (n=190, 93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.86","value":"73.7"},{"groupId":"OG001","spread":"18.87","value":"77.3"}]}],"title":"Physical Functioning Scale: Baseline (n=228, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.71","value":"78.6"},{"groupId":"OG001","spread":"16.24","value":"80.9"}]}],"title":"Physical Functioning Scale: Cy4D1(n=189,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"58.4"},{"groupId":"OG001","spread":"22.9","value":"57.4"}]}],"title":"Global Health Status Scale: Baseline (n=226, 111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.03","value":"66.7"},{"groupId":"OG001","spread":"20.56","value":"63.4"}]}],"title":"Global Health Status Scale: Cy4D1(n=189,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.18","value":"76.1"},{"groupId":"OG001","spread":"28.35","value":"74.7"}]}],"title":"Role Functioning Scale: Baseline(n=227,110)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.64","value":"79.7"},{"groupId":"OG001","spread":"21.35","value":"81.5"}]}],"title":"Role Functioning Scale: Cy4D1(n=189,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.52","value":"86.3"},{"groupId":"OG001","spread":"25.34","value":"83.3"}]}],"title":"Social Functioning Scale:Baseline(n=226,110)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.97","value":"87.8"},{"groupId":"OG001","spread":"19.38","value":"85.5"}]}],"title":"Social Functioning Scale: Cy4D1(n=190,93)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.12","value":"29.4"},{"groupId":"OG001","spread":"32.98","value":"31.5"}]}],"title":"Insomnia Scale: Baseline (n=228,111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.13","value":"20.6"},{"groupId":"OG001","spread":"29.13","value":"24.4"}]}],"title":"Insomnia Scale: Cy4D1(n=189,93)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[First infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"MEAN","populationDescription":"ITT population. Here, n signifies the number of participants who were evaluated for specified categories.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 4 Day 1 (Cy4D1)","title":"European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score","type":"SECONDARY","unitOfMeasure":"unit on a scale"}